Updated Jul 16, 2026
Sullivan Christopher Ryan has filed 5 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.89M.
Christopher Ryan Sullivan is associated with Avalo Therapeutics, Inc., as indicated by recent SEC filings. Specific details about his role or contributions to the company are not widely documented in public sources, suggesting he may not be a widely recognized figure in the industry.
| Role | Insider |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-12 | AVTX | Avalo Therapeutics, Inc. | F — Tax withholding / forfeiture | 138 | $13.10 | $2K |
| 2026-05-26 | AVTX | Avalo Therapeutics, Inc. | A — Grant or award | 39.9K | $0.00 | |
| 2026-05-11 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 18.6K | $24.12 | $449K |
| 2026-05-11 | AVTX | Avalo Therapeutics, Inc. | M — Option exercise | 18.6K | $9.88 | $184K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 8.9K | $22.57 | $201K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 9.2K | $21.37 | $197K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 2.7K | $20.76 | $56K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 12.3K | $19.28 | $238K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 13.8K | $18.55 | $257K |
| 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | M — Option exercise | 47.0K | $8.04 | $378K |
| 2026-05-01 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 8.5K | $13.23 | $112K |
| 2026-05-01 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale | 8.5K | $13.09 | $111K |
| 2026-04-03 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.8K | $17.57 | $31K |
| 2026-04-03 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale [10b5-1] | 6.2K | $17.02 | $106K |
| 2026-04-03 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale [10b5-1] | 7.5K | $16.83 | $126K |
| 2026-04-03 | AVTX | Avalo Therapeutics, Inc. | S — Open-market sale [10b5-1] | 500 | $15.86 | $8K |
| 2026-03-31 | AVTX | Avalo Therapeutics, Inc. | F — Tax withholding / forfeiture | 8.2K | $13.89 | $114K |
| 2026-03-31 | AVTX | Avalo Therapeutics, Inc. | M — Option exercise | 24.2K | — |
Christopher Ryan Sullivan is associated with Avalo Therapeutics, Inc., as indicated by recent SEC filings. Specific details about his role or contributions to the company are not widely documented in public sources, suggesting he may not be a widely recognized figure in the industry.…
5 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 12 open-market sales ($1.89M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Sullivan Christopher Ryan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.